|Bid||0.0100 x 1000|
|Ask||2.4000 x 3100|
|Day's Range||1.7000 - 1.7900|
|52 Week Range||1.0100 - 4.9000|
|Beta (3Y Monthly)||2.78|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.00|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! As an investor, I look for investments which does not compromise one fundamental factor for...
This month, we saw the Benitec Biopharma Limited (ASX:BLT) up an impressive 48%. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. In fact, theRead More...
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have Read More...
SYDNEY and HAYWARD, Calif. , Dec. 21, 2018 /PRNewswire/ -- Benitec Biopharma (ASX: BLT, NADSAQ: BNTC) (the "Company"), a clinical-stage biotechnology company developing novel genetic medicines ...
The direct benefit for Benitec Biopharma Limited (ASX:BLT), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
SYDNEY , Sept. 19, 2018 /PRNewswire/ -- Benitec Biopharma Limited ("Benitec" or the "Company") (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a clinical-stage biotechnology company developing ...
Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Shares of Pfizer may have ended up flat yesterday but it wasn't the greatest news day for the pharmaceutical giant. President Trump took to Twitter to raise his concerns on the company as well as other drug makers for recently increasing prices. Shares of Benitec Biopharma was a big winner and even hit a new high after announcing a licensing agreement with Axovant.
New entrant Biotricity (BTCY) is jumping into the same market with a potentially superior product and under-appreciated market valuation. BTCY expects to be prepared with two more products in the next 6-9 months, and they could all be on the market by the end of 2019. NEW YORK, NY / ACCESSWIRE / July 10, 2018 / With their latest investor update, Biotricity Inc. (BTCY) just dropped a major hint that most investors have been missing so far... key product updates are coming later this year.
Axovant and Benitec Biopharma Rise on Gene Therapy Licensing DealAxovant and Benitec Biopharma enter into a licensing deal
Shares of the biopharmaceutical company rose 5% in early morning trading Monday after it announced it had bought the rights to a new gene therapy treatment designed for a rare form of muscular dystrophy from Benitec Biopharma Ltd. Axovant rose 12 cents -- or 5% -- to $2.68 a share on news of the deal while Benitec skyrocketed $1.52 -- or 67.8% --$3.76. The two companies also entered into a research collaboration to develop five more treatments meant to target neurological disorders.
- Benitec to receive upfront cash payment of US$10 million with additional cash payments totalling US$17.5 million (a total of US$27.5M ) upon completion of near-term milestones for BB-301, now named AXO-AAV-OPMD ...
NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative therapeutics based on a combination of gene therapy with its patented gene-silencing technology called ddRNAi or 'expressed RNAi', today reported its consolidated financial results for the 2018 fiscal third quarter to 31 March 2018 (3Q FY18), and highlighted recent progress advancing its pipeline.